- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00901199
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
July 20, 2021 updated by: Elliott Vichinsky
Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
This is a pilot study looking at the safety and efficacy of giving combination chelation with deferasirox and deferoxamine.
The hypothesis is that combination chelation is safe in decreasing overall iron in patients with thalassemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a phase two pilot clinical trial designed to evaluate the safety and efficacy of the combination of deferasirox and deferoxamine in transfusion dependent thalassemia with a range of systemic iron burden.
The duration of combined therapy was 12 months.
Changes in liver iron concentration, ferritin, myocardial iron, and serum creatinine was monitored.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- CHRCO
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Transfusion Dependent Thalassemia
- If iron between 5-15 mg/g dry liver by SQUID, subject must have a documented endocrinopathy or cardiac finding
- Older than 8 years
Exclusion Criteria:
- Participating on another interventional clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Deferasirox (Exjade) and Deferoxamine (DFO)
All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.
|
All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week.
All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week.
The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of Combined Treatment With Deferasirox and Deferoxamine Over 12 Months
Time Frame: 12 months
|
Change in liver iron concentration from baseline to 12 months with the use of combined chelation therapy.
The change was calculated as the liver iron concentration at 12 months minus the value at baseline.
|
12 months
|
Change in Serum Creatinine During 12 Months Combined Chelation Therapy
Time Frame: 12 months
|
Comparison of average serum creatinine over 12 months of combined chelation therapy compared with baseline serum creatinine.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Elliot Vichinsky, MD, UCSF Benioff Children's Hospital Oakland
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (ACTUAL)
October 1, 2012
Study Completion (ACTUAL)
October 1, 2012
Study Registration Dates
First Submitted
May 12, 2009
First Submitted That Met QC Criteria
May 12, 2009
First Posted (ESTIMATE)
May 13, 2009
Study Record Updates
Last Update Posted (ACTUAL)
August 12, 2021
Last Update Submitted That Met QC Criteria
July 20, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Iron Metabolism Disorders
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Iron Overload
- Thalassemia
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Siderophores
- Deferasirox
- Deferoxamine
Other Study ID Numbers
- CICL670AUS24T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Overload
-
Novartis PharmaceuticalsCompletedTransfusional Iron OverloadItaly
-
ApoPharmaCompletedTransfusional Iron OverloadEgypt, Cyprus, Oman, Saudi Arabia, Turkey
-
Novartis PharmaceuticalsCompletedChronic Iron OverloadGermany
-
Novartis PharmaceuticalsNot yet recruiting
-
Novartis PharmaceuticalsCompletedCardiac Iron OverloadTaiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ApoPharmaCompletedIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Greece, Italy
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ShireTerminatedIron Overload Due to Repeated Red Blood Cell TransfusionsCanada, United States, Thailand, Italy, United Kingdom
-
ShireTerminatedPharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation TherapyIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Lebanon, Italy, Egypt
Clinical Trials on Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
-
Novartis PharmaceuticalsTerminatedCardiac Iron Overload | Transfusion-dependent β-thalassemia PatientsGreece
-
Novartis PharmaceuticalsCompletedTransfusional Hemosiderosis | Transfusional Iron OverloadTaiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
-
Weill Medical College of Cornell UniversityUnknownThalassemiaUnited States
-
Novartis PharmaceuticalsCompletedIron Overload | Sickle Cell Disease | Hemolytic AnemiaUnited States, Canada
-
Boston Children's HospitalNovartisCompletedSickle Cell Disease | Thalassemia Major | Transfusion-dependent HemachromatosisUnited States